6855 logo

Ascentage Pharma Group International SHSC:6855 Stock Report

Last Price

HK$43.75

Market Cap

HK$13.6b

7D

-3.0%

1Y

58.8%

Updated

02 Jan, 2025

Data

Company Financials +

Ascentage Pharma Group International

SHSC:6855 Stock Report

Market Cap: HK$13.6b

6855 Stock Overview

A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More details

6855 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Revenue is forecast to grow 23.29% per year

Earnings have grown 10.4% per year over the past 5 years

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


My Notes

Capture your thoughts, links and company narrative

Ascentage Pharma Group International Competitors

Shanghai Henlius Biotech

SEHK:2696

HK$12.8b

Everest Medicines

SEHK:1952

HK$16.0b

Akeso

SEHK:9926

HK$52.6b

Shanghai Haohai Biological Technology

SEHK:6826

HK$12.9b

Price History & Performance

Summary of share price highs, lows and changes for Ascentage Pharma Group International
Historical stock prices
Current Share PriceHK$43.75
52 Week HighHK$48.85
52 Week LowHK$15.42
Beta1.13
1 Month Change6.45%
3 Month Change3.67%
1 Year Change58.80%
3 Year Changen/a
5 Year Changen/a
Change since IPO99.32%

Recent News & Updates

Recent updates

Shareholder Returns

6855HK BiotechsHK Market
7D-3.0%-3.2%-2.4%
1Y58.8%-10.2%16.2%

Return vs Industry: 6855 exceeded the Hong Kong Biotechs industry which returned -8.4% over the past year.

Return vs Market: 6855 exceeded the Hong Kong Market which returned 19.4% over the past year.

Price Volatility

Is 6855's price volatile compared to industry and market?
6855 volatility
6855 Average Weekly Movement6.4%
Biotechs Industry Average Movement9.8%
Market Average Movement8.2%
10% most volatile stocks in HK Market16.5%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6855 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6855's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009574Dajun Yangwww.ascentage.cn

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.

Ascentage Pharma Group International Fundamentals Summary

How do Ascentage Pharma Group International's earnings and revenue compare to its market cap?
6855 fundamental statistics
Market capHK$13.56b
Earnings (TTM)-HK$383.86m
Revenue (TTM)HK$962.13m

14.1x

P/S Ratio

-35.3x

P/E Ratio

Is 6855 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6855 income statement (TTM)
RevenueCN¥903.03m
Cost of RevenueCN¥27.45m
Gross ProfitCN¥875.58m
Other ExpensesCN¥1.24b
Earnings-CN¥360.28m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.16
Gross Margin96.96%
Net Profit Margin-39.90%
Debt/Equity Ratio216.3%

How did 6855 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 05:47
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascentage Pharma Group International is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang HuangBofA Global Research
Jin ZhangChina International Capital Corporation Limited
Wangbin ZhouChina International Capital Corporation Limited